

# Japan Virtual Clinical Trials Market, By Study (Interventional, Observational, Expanded Access), By Indication (CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Others), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, Opportunity, Competition & Forecast, 2020-2030F

Market Report | 2024-08-02 | 82 pages | TechSci Research

# **AVAILABLE LICENSES:**

- Single User License \$3500.00
- Multi-User License \$4500.00
- Custom Research License \$7500.00

# **Report description:**

Japan Virtual Clinical Trials Market was valued at USD 560.55 million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.45% through 2030. The Japan Virtual Clinical Trials (VCT) market is rapidly evolving due to advancements in technology, regulatory developments, and shifting industry trends. This market is experiencing significant growth driven by the increasing demand for flexible and efficient clinical trial methodologies. Pharmaceutical companies, biotechnology firms, and research organizations are leveraging virtual trial capabilities to enhance efficiency, reduce costs, and improve patient recruitment and retention. Industry reports project continued robust growth, supported by technological advancements and an evolving regulatory landscape. Despite challenges, the future outlook for the Japan VCT market is positive, with ongoing innovation and adaptation expected to drive further expansion and success.

# Key Market Drivers

# Technological Advancements

Technological advancements play a crucial role in driving the growth of the Japan Virtual Clinical Trials (VCT) market. These advancements enhance the efficiency, reach, and effectiveness of clinical trials by integrating innovative digital tools and platforms. The proliferation of wearable devices and sensors has significantly transformed the way clinical trials are conducted. These devices, which can monitor a range of physiological parameters such as heart rate, blood pressure, and glucose levels, provide continuous and real-time data from patients. In virtual trials, this capability allows researchers to track patient health and treatment responses without requiring frequent site visits. This continuous monitoring improves data accuracy and provides a

comprehensive view of patient well-being. Mobile health (mHealth) applications are another key technological advancement driving VCT growth. These apps enable patients to record and transmit health information, participate in remote assessments, and communicate with healthcare providers. The integration of mHealth applications into virtual trials streamlines data collection and enhances patient engagement by providing a convenient platform for managing trial-related activities. Japan's healthcare sector is projected to expand significantly through digital transformation. Currently valued at USD 0.28 trillion, the industry is anticipated to grow to USD 0.65 trillion by 2040, driven by the pandemic's impact on healthcare strategies and the economy. The government expects substantial socioeconomic benefits from this digitalization process. Japan is advancing the digitization of data across long-term care and disability services, establishing systems for digital prescriptions and the digitization of welfare services. These initiatives are expected to enhance services in telemedicine, telepharmacy, medical applications, devices, and the implementation of smart hospitals utilizing artificial intelligence.

Telemedicine platforms have become integral to virtual clinical trials by facilitating remote consultations between patients and healthcare providers. These platforms support video conferencing, secure messaging, and virtual consultations, reducing the need for in-person visits. By enabling real-time interactions and follow-ups, telemedicine platforms enhance patient convenience and broaden the reach of clinical trials, making them accessible to participants regardless of their geographical location. The use of electronic consent (eConsent) systems has streamlined the consent process in virtual trials. These systems allow patients to review, sign, and submit consent forms electronically, eliminating the need for physical paperwork. This digital approach not only speeds up the consent process but also improves compliance and data accuracy, contributing to the overall efficiency of virtual trials. Advances in data analytics and artificial intelligence (AI) have revolutionized the way data is collected, processed, and analyzed in virtual trials. Al-powered tools can analyze large volumes of data in real-time, identify patterns, and generate insights that inform trial design and execution. This capability enables researchers to make data-driven decisions, optimize trial protocols, and improve the accuracy of outcomes. Predictive analytics, supported by AI, allows for the anticipation of potential issues and the optimization of trial parameters. By analyzing historical data and identifying trends, researchers can adapt trial protocols dynamically to enhance efficacy and safety. This adaptive approach improves the flexibility and responsiveness of virtual trials, making them more effective in addressing evolving research needs.

Technological advancements have also focused on improving the interoperability of digital health systems. The integration of electronic health records (EHRs), clinical trial management systems (CTMS), and remote monitoring platforms ensures seamless data flow and reduces the risk of errors. Effective integration of these systems supports comprehensive data management and enhances the efficiency of virtual trials. Blockchain technology is increasingly being explored for its potential to enhance data security and integrity in virtual trials. By providing a decentralized and immutable ledger for recording transactions, blockchain ensures that trial data is secure, transparent, and tamper-proof. This technology addresses concerns related to data privacy and compliance, fostering trust and reliability in virtual trials.

### **Patient-Centric Trends**

Patient-centric trends are pivotal in driving the growth of the Japan Virtual Clinical Trials (VCT) market. These trends focus on enhancing the patient experience and addressing their needs and preferences, which significantly influences the adoption and success of virtual trials. One of the most compelling drivers of VCT growth is the emphasis on convenience and flexibility for patients. Virtual trials minimize the need for frequent in-person visits to clinical sites, which can be particularly challenging for patients with mobility issues, busy schedules, or those residing in remote areas. By allowing patients to participate from their homes, virtual trials reduce travel burdens and accommodate diverse patient needs, making it easier for them to engage in clinical research. Virtual trials offer flexible participation options, including remote data collection and virtual consultations. This flexibility aligns with patients' preferences for managing their health on their terms, and it helps to accommodate various lifestyles and commitments. The ability to participate in trials without rigid time constraints enhances overall patient satisfaction and encourages greater involvement in research studies.

Patient-centric virtual trials often include features that enhance transparency and communication between patients and research teams. Digital platforms facilitate regular updates, feedback, and interaction, which empower patients by keeping them informed about their progress and trial developments. Enhanced communication helps build trust and encourages active participation, as patients feel more involved and valued throughout the trial process. Virtual trials leverage technology to provide personalized experiences tailored to individual patient needs. For example, digital health tools can track patient-specific data, such as

symptoms and treatment responses, allowing for more individualized care and adjustments to trial protocols. Personalization not only improves patient outcomes but also makes the trial process more relevant and engaging for participants. Virtual trials expand the potential patient pool by overcoming geographical barriers. Patients who might have otherwise been excluded due to distance or lack of access to specialized medical facilities can now participate in trials. This broader reach enhances recruitment efforts and increases the likelihood of enrolling a diverse patient population, which is crucial for the generalizability of trial results. The convenience and flexibility of virtual trials contribute to higher retention rates. Patients are more likely to remain engaged in a study that minimizes disruptions to their daily lives and offers support through digital platforms. Features such as reminders, easy access to trial materials, and virtual check-ins help maintain patient involvement and reduce dropout rates.

Virtual trials are designed to reduce the physical and emotional burden on patients by streamlining the trial process and providing support through digital means. For instance, remote monitoring and digital assessments minimize the need for frequent visits to clinical sites, while virtual support tools offer resources and guidance to help patients manage their participation effectively. The integration of digital tools that assist with managing trial-related tasks, such as medication adherence reminders and symptom tracking, enhances the overall patient experience. These tools support patients in adhering to trial protocols and managing their health more effectively, contributing to a positive trial experience and better outcomes. There is a growing expectation among patients for clinical research models that prioritize their needs and preferences. Virtual trials align with this expectation by offering more patient-friendly approaches and addressing common barriers to participation. This alignment not only improves patient satisfaction but also drives the adoption of virtual trials as a preferred method for conducting clinical research. Patient-centric virtual trials often incorporate feedback from participants to continuously improve the trial experience. By actively seeking and integrating patient input, researchers can refine trial protocols, address concerns, and enhance overall satisfaction. This iterative approach helps build stronger patient relationships and ensures that the trial process remains responsive to patient needs.

# Advances in Data Analytics

Advances in data analytics are a significant driver of growth in the Japan Virtual Clinical Trials (VCT) market. These advancements enhance the effectiveness, efficiency, and scalability of virtual trials by enabling more sophisticated data management and analysis techniques. Advances in data analytics facilitate the continuous collection and real-time analysis of patient data through digital health tools, such as wearables and remote monitoring devices. This capability allows for the ongoing assessment of patient health metrics, treatment responses, and adverse events. By providing real-time insights, researchers can make timely decisions, adjust trial protocols, and ensure that trials remain aligned with their objectives. The ability to analyze data in real time allows for immediate feedback to both patients and researchers. This feedback loop enhances the responsiveness of virtual trials, enabling quick adjustments based on emerging data trends. Such adaptability is crucial for optimizing trial designs and improving outcomes, particularly in dynamic and complex research environments.

Advances in data analytics have led to the development of unified platforms that integrate data from various sources, including electronic health records (EHRs), remote monitoring tools, and patient-reported outcomes. These platforms enable comprehensive data management by consolidating information into a single, accessible system. The integration of diverse data sources provides a holistic view of patient health and trial progress, improving the quality and depth of analysis. Technological advancements in data interoperability address the challenge of integrating data from disparate systems. Standardized data formats and interoperability frameworks ensure seamless data exchange between different platforms and technologies. This improved connectivity enhances the efficiency of data collection and analysis, facilitating more effective virtual trials. Modern data analytics tools employ advanced statistical techniques to analyze complex datasets. Methods such as multivariate analysis, Bayesian modeling, and machine learning algorithms enable researchers to identify patterns, correlations, and insights that may not be apparent through traditional analysis. These sophisticated techniques enhance the ability to detect significant effects, predict outcomes, and refine trial methodologies. Predictive analytics, powered by machine learning and Al, allows researchers to forecast future trends and potential outcomes based on historical data. In virtual trials, predictive models can estimate patient responses, identify potential issues, and optimize trial designs. This foresight helps in proactively addressing challenges and improving the overall efficiency of the trial process.

Advances in data analytics support the growth of personalized and precision medicine by enabling the analysis of patient-specific data, such as genetic profiles and biomarkers. Virtual trials can leverage this data to tailor treatments to individual patients,

enhancing the relevance and effectiveness of interventions. Precision medicine approaches, facilitated by advanced analytics, improve trial outcomes and contribute to the development of targeted therapies. Data analytics tools enable more precise patient stratification by analyzing various factors, including demographics, medical history, and genetic information. This stratification allows for the identification of patient subgroups that are more likely to benefit from specific treatments. By targeting these subgroups, virtual trials can achieve more accurate and meaningful results. Technological advancements in data analytics include automated data validation and quality control processes. These tools detect anomalies, inconsistencies, and errors in real time, ensuring the accuracy and reliability of trial data. By maintaining high data quality, researchers can make more informed decisions and produce more credible results. Advances in data analytics also encompass enhanced data security measures, including encryption, access controls, and compliance with regulatory standards. Ensuring the integrity and confidentiality of patient data is crucial for maintaining trust and meeting regulatory requirements. Improved security measures support the adoption of virtual trials by addressing concerns related to data protection.

# Key Market Challenges

## Regulatory and Compliance Issues

Navigating the regulatory landscape for virtual clinical trials in Japan can be complex. Although regulatory bodies like the Pharmaceuticals and Medical Devices Agency (PMDA) are evolving their frameworks to accommodate virtual trials, there remains a lack of standardized guidelines specifically tailored to VCTs. This complexity can create uncertainty and hinder the adoption of virtual trials, as sponsors and researchers must ensure compliance with various regulations related to data security, patient consent, and trial conduct.

Virtual trials involve the collection, storage, and transmission of sensitive health data, which raises significant data privacy and security concerns. Ensuring compliance with stringent data protection regulations, such as the Act on the Protection of Personal Information (APPI) in Japan, is critical. The need for robust cybersecurity measures and data handling protocols can be a barrier for organizations looking to implement virtual trials, as they must invest in advanced technologies and practices to safeguard patient information.

# Technological and Infrastructure Limitations

The success of virtual clinical trials depends heavily on the availability and use of digital health technologies by both patients and clinical sites. In Japan, there is variability in technological access and digital literacy among different patient populations. This disparity can affect patient participation and engagement, particularly in rural or underserved areas where access to high-speed internet and advanced digital devices may be limited. Ensuring that all potential participants have the necessary technology and skills to engage in virtual trials remains a significant challenge.

Virtual trials require seamless integration of various digital tools and platforms, including electronic health records (EHRs), remote monitoring devices, and telemedicine systems. Achieving interoperability between these systems can be challenging due to differences in technology standards and data formats. The lack of standardized protocols for data exchange and integration can hinder the efficiency and effectiveness of virtual trials, impacting data accuracy and trial outcomes. Patient and Investigator Engagement

# While virtual trials offer convenience, they also face challenges in recruiting and retaining participants. Patients may be hesitant to participate in virtual trials due to concerns about the quality of remote care, the unfamiliarity of virtual platforms, or a lack of access to necessary technology. Additionally, the need for patients to self-manage their participation and provide accurate data remotely can be a barrier to engagement, particularly for those with limited digital literacy or technical support.

Clinical investigators and site staff need to adapt to new virtual trial methodologies and technologies. This adaptation involves significant training and adjustment to ensure they can effectively manage remote patient interactions, data collection, and trial oversight. The transition from traditional to virtual trial methods can be challenging, particularly for investigators who are accustomed to in-person interactions and manual processes. Ensuring that investigators are adequately trained and supported is essential for the successful implementation of virtual trials.

### Key Market Trends

### Advancements in Digital Health Technologies

The rapid evolution of digital health technologies, including wearables and remote monitoring tools, is a major driver of growth in the VCT market. These technologies enable continuous and real-time monitoring of patient health metrics, such as vital signs,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

activity levels, and biometric data. By providing precise and ongoing data collection, they enhance the ability to track patient responses to treatments and adjust protocols dynamically. The adoption of these tools is making it easier to conduct complex trials, particularly for chronic and long-term conditions, and supports the shift towards decentralized and patient-centric research models.

The increased use of telemedicine platforms and virtual consultations is also contributing to the growth of VCTs. These platforms facilitate remote interactions between patients and healthcare professionals, allowing for regular check-ups, consultations, and follow-up appointments without the need for physical visits. This trend not only improves patient convenience but also extends the reach of clinical trials to a broader patient population, including those in remote or underserved areas. The integration of telemedicine into VCTs helps streamline trial processes and reduce operational costs.

## Regulatory Evolution and Support

Regulatory bodies in Japan, such as the Pharmaceuticals and Medical Devices Agency (PMDA), are increasingly adapting their frameworks to accommodate and support virtual clinical trials. This includes the development of guidelines that address the unique challenges and requirements of VCTs, such as data security, remote patient monitoring, and digital consent. The growing acceptance and endorsement of virtual trial methodologies by regulatory agencies are facilitating smoother approvals and encouraging more sponsors to pursue VCTs.

As virtual trials involve the collection and management of sensitive health data, there is a strong focus on ensuring data integrity and security. Advances in cybersecurity measures and data management practices are addressing these concerns and enhancing the credibility of VCTs. By implementing robust security protocols and compliance measures, regulatory bodies are fostering an environment where virtual trials can be conducted with confidence in data protection and regulatory adherence. Increased Focus on Patient-Centric Approaches

There is a growing emphasis on patient-centric approaches in clinical research, which prioritizes the needs and preferences of patients. Virtual trials align well with this trend by offering greater convenience and flexibility, thereby improving patient engagement and recruitment. By reducing the need for frequent site visits and accommodating patients' schedules, virtual trials make participation more accessible and appealing. This patient-centric model not only boosts enrollment rates but also enhances the overall quality and reliability of trial data.

The rise of personalized and precision medicine is driving the need for more targeted and individualized clinical trials. Virtual trials are well-suited to this trend as they enable the integration of advanced diagnostic tools and genetic information to tailor treatments to specific patient profiles. The ability to conduct remote assessments and monitor individualized treatment responses supports the development of more precise and effective therapies. As personalized medicine continues to advance, the demand for virtual trials that can accommodate these sophisticated approaches is expected to grow.

# Segmental Insights

### Indication Insights

Based on the category of Indication, the Oncology segment emerged as the dominant in the market for Japan Virtual Clinical Trials in 2024. Oncology trials often involve complex protocols and a need for precision in patient monitoring and data collection. Virtual clinical trials cater to these needs by enabling remote patient monitoring, which is crucial for tracking the progression of cancer and the effects of treatment in real-time. This capability is particularly beneficial for oncology, where continuous and precise data is required to assess treatment efficacy and patient responses. The oncology sector is one of the most active areas in clinical research, with numerous ongoing studies aimed at developing new therapies and targeted treatments. The demand for innovative treatments drives the need for efficient trial designs, including virtual trials. The ability to reach a broad patient population and gather extensive data remotely aligns well with the needs of oncology research, where patient participation is critical. Oncology trials often require significant patient enrollment due to the need for large sample sizes to ensure statistically significant results. Virtual clinical trials facilitate broader patient recruitment by overcoming geographical barriers and enabling participation from remote locations. This expanded reach is essential for oncology trials, which frequently involve patients with specific cancer types or stages, who may be dispersed across various regions. Cancer patients often face physical challenges and constraints that make frequent visits to clinical sites difficult. Virtual trials offer the flexibility and convenience of remote participation, reducing

the burden on patients who are undergoing cancer treatment. This patient-centric approach improves enrollment and retention rates, which are critical for the success of oncology trials. Oncology trials generate vast amounts of data related to biomarkers,

genetic information, and treatment responses. Virtual trials leverage advanced data management systems to handle and analyze this data efficiently. The ability to integrate various data sources and perform real-time analysis enhances the overall effectiveness of oncology research and accelerates the development of new treatments. These factors collectively contribute to the growth of this segment.

# **Regional Insights**

Kanto emerged as the dominant in the Japan Virtual Clinical Trials market in 2024, holding the largest market share in terms of value. The Kanto Region is home to Japan's largest concentration of biopharmaceutical companies, clinical research organizations (CROs), and contract research organizations (CROs). This concentration provides a robust ecosystem that supports the development and execution of virtual clinical trials. The presence of these organizations ensures access to a skilled workforce, advanced technology, and extensive research networks, all of which are crucial for the successful implementation of VCTs. The Kanto Region benefits from a highly developed technological infrastructure, including high-speed internet and advanced data management systems. This technological edge facilitates the implementation of virtual trial protocols, which rely heavily on digital tools for data collection, patient monitoring, and remote consultations. The region's technological readiness supports the seamless execution of virtual trials and attracts companies seeking a reliable environment for their clinical studies. The Kanto Region, particularly Tokyo, is the epicenter of regulatory oversight in Japan. The presence of the Pharmaceuticals and Medical Devices Agency (PMDA) and other regulatory bodies ensures that virtual clinical trials conducted in this region adhere to stringent standards and guidelines. This regulatory rigor enhances the credibility and acceptance of VCTs, making the region a preferred choice for sponsors looking to ensure compliance with both Japanese and international regulations.

The Kanto Region has a large and diverse population, providing a substantial patient pool for clinical trials. The region's high population density and diverse demographics facilitate easier patient recruitment and retention for virtual trials. This is particularly advantageous for studies requiring specific patient profiles or large sample sizes. The Japanese government and local authorities in the Kanto Region offer various financial and research incentives to encourage the growth of clinical research and innovation. These incentives include funding opportunities, tax breaks, and grants for companies engaged in clinical research, including virtual trials. Such support reduces the financial burden on trial sponsors and enhances the region's attractiveness as a hub for VCTs.

Key Market Players ICON, plc Parexel International (MA) Corporation IQVIA Inc Laboratory Corporation of America Holdings LEO Innovation LabLEO Innovation Lab Medidata Oracle NOW Foods Medable Inc CROPRIME Ltd

Report Scope:

In this report, the Japan Virtual Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dapan Virtual Clinical Trials Market, By Study:

- o Interventional
- o Observational
- o Expanded Access
- Dapan Virtual Clinical Trials Market, By Indication:
- o CNS
- o Autoimmune/Inflammation
- o Cardiovascular Disease

- o Metabolic/Endocrinology
- o Infectious Disease
- o Oncology
- o Genitourinary
- o Ophthalmology
- o Others
- Dapan Virtual Clinical Trials Market, By Phase:
- o Phase I
- o Phase II
- o Phase III
- o Phase IV
- Dapan Virtual Clinical Trials Market, By Region:
- o Hokkaido
- o Tohoku
- o Kanto
- o Chubu
- o Kansai
- o Chugoku
- o Shikoku
- o Kyushu
- Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Japan Virtual Clinical Trials Market.

Available Customizations:

Japan Virtual Clinical Trials market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

**Company Information** 

Detailed analysis and profiling of additional market players (up to five).

# **Table of Contents:**

- 1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
- 2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
- 3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players

- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
- 4. Voice of Customer
- 5. Japan Virtual Clinical Trials Market Outlook
- 5.1. Market Size & Forecast
- 5.1.1. By Value
- 5.2. Market Share & Forecast
- 5.2.1. By Study (Interventional, Observational, Expanded Access)

5.2.2. By Indication (CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease,

- Oncology, Genitourinary, Ophthalmology, Others)
- 5.2.3. By Phase (Phase I, Phase II, Phase III, Phase IV)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
- 6. Hokkaido Virtual Clinical Trials Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Study
- 6.2.2. By Indication
- 6.2.3. By Phase
- 7. Tohoku Virtual Clinical Trials Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Study
- 7.2.2. By Indication
- 7.2.3. By Phase
- 8. Kanto Virtual Clinical Trials Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Study
- 8.2.2. By Indication
- 8.2.3. By Phase
- 9. Chubu Virtual Clinical Trials Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Study
- 9.2.2. By Indication
- 9.2.3. By Phase
- 10. Kansai Virtual Clinical Trials Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Study

10.2.2. By Indication 10.2.3. By Phase 11. Chugoku Virtual Clinical Trials Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Study 11.2.2. By Indication 11.2.3. By Phase 12. Shikoku Virtual Clinical Trials Market Outlook 12.1. Market Size & Forecast 12.1.1. By Value 12.2. Market Share & Forecast 12.2.1. By Study 12.2.2. By Indication 12.2.3. By Phase 13. Kyushu Virtual Clinical Trials Market Outlook 13.1. Market Size & Forecast 13.1.1. By Value 13.2. Market Share & Forecast 13.2.1. By Study 13.2.2. By Indication 13.2.3. By Phase 14. Market Dynamics 14.1. Drivers 14.2. Challenges 15. Market Trends & Developments 15.1. Recent Developments 15.2. Product Launches 15.3. Mergers & Acquisitions 16. Japan Virtual Clinical Trials Market: SWOT Analysis 17. Competitive Landscape 17.1. ICON. plc 17.1.1. **Business Overview** 17.1.2. Product & Service Offerings 17.1.3. **Recent Developments** 17.1.4. Financials (If Listed) 17.1.5. Key Personnel 17.1.6. **SWOT** Analysis 17.2. Parexel International (MA) Corporation 17.3. IQVIA Inc 17.4. Laboratory Corporation of America Holdings 17.5. LEO Innovation LabLEO Innovation Lab 17.6. Medidata 17.7. Oracle

- 17.8. NOW Foods
- 17.9. Medable Inc

17.10.CROPRIME Ltd

18. Strategic Recommendations

19. About Us & Disclaimer



# Japan Virtual Clinical Trials Market, By Study (Interventional, Observational, Expanded Access), By Indication (CNS, Autoimmune/Inflammation, Cardiovascular Disease, Metabolic/Endocrinology, Infectious Disease, Oncology, Genitourinary, Ophthalmology, Others), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, Opportunity, Competition & Forecast, 2020-2030F

Market Report | 2024-08-02 | 82 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

# **ORDER FORM:**

Select license	License	Price
	Single User License	\$3500.00
	Multi-User License	\$4500.00
	Custom Research License	\$7500.00
	VAT	
	Total	

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*		
First Name*	Last Name*		
Job title*			
Company Name*	EU Vat / Tax ID / NIP	number*	

Address*	City*	
Zip Code*	Country*	
	Date	2025-05-08
	Signature	